HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
Venetoclax Combination Shows Anti-Myeloma Effects
Posted: Aug 26, 2016
Venetoclax Combination Shows Anti-Myeloma Effects image

In a recent article on OncLive, Asher A. Chanan-Khan, MD, of the Mayo Clinic in Jacksonville, Florida describes how a three-drug combination using bortezomib, dexamethasone and a new Bcl-2 inhibitor called venetoclax shows benefit for heavily pretreated patients.

Results from a recent study showed an overall response rate (ORR) of 47%. 

  • 6% achieved stringent complete response
  • 3% achieved complete response
  • 19% of patients achieved very good partial response
  • 25% showed progressive disease

According to Dr. Chanan-Khan, myeloma survival is boosted by the proteins BCL-2 and MCL-1. Bortezomib (Velcade) stops the MCL-1 activity and venetoclax is an oral drug that both inhibits BCL-2 as well as enhances the activity of bortezomib in myeloma cells and mouse models.

Investigators also looked at overall response rate (ORR) by myeloma genetics, trying to identify if the combination is more or less effective for specific patients. The overall response rate for each type of myeloma was as follows:

  • 75% for 11;14
  • 33% for 4;14
  • 25% or del17p
  • 64% for hyperdiploid patients

Venetoclas was FDA approved for chronic lymphocytic leukemia (CLL) patients with a del17p chromosomal abnormality in April of this year. New drugs that improve responses in myeloma patients are needed and welcome.

“There is a dire unmet need of new treatments in multiple myeloma; this combination provides broad inhibition, which is important,” said lead study author Asher A. Chanan-Khan, MD

To read the full article, click here. To find open clinical trials using venetoclax, click here:

Venetoclax Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube